Anastasia Lambrianides - Genetic Mutations

Author Information

Anastasia Lambrianides is affiliated with the Cyprus School of Molecular Medicine at The Cyprus Institute of Neurology and Genetics, located in Nicosia, Cyprus. Her research primarily focuses on the genetic and immunological aspects of neurological diseases, with a particular emphasis on multiple sclerosis and autoimmune disorders. Her work often explores the role of antibodies and immune responses in disease mechanisms.

Research Contributions

Anastasia Lambrianides has made significant contributions to understanding the immunological factors involved in neurological diseases. Her research includes the characterization of antibody responses against SARS-CoV-2 in the Cypriot population and the investigation of the role of toll-like receptors in multiple sclerosis. She has also explored the potential autoimmune mechanisms in Parkinson's disease and studied the implications of antiphospholipid antibodies in multiple sclerosis. Her work is instrumental in identifying biomarkers and understanding the pathogenesis of these diseases.

Aliases

Anastasia Lambrianides is also known by the aliases A Lambrianides and A. Lambrianides in various publications and academic circles.

Publication and Citation Metrics

Metric	Value
Citation Count	779
h-index	13
Paper Count	60

Publications:

Antibodies to blood coagulation components are implicated in patients with multiple sclerosis.

DOI: 10.1016/j.msard.2022.103775

Year: 2022

Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population

DOI: 10.3390/microorganisms10010085

Year: 2021

The expression profile of virus-recognizing toll-like receptors in natural killer cells of Cypriot multiple sclerosis patients

DOI: 10.1186/s13104-020-05300-1

Year: 2020

Complete sequence analysis of human toll-like receptor 3 gene in natural killer cells of multiple sclerosis patients.

DOI: 10.1016/j.msard.2019.05.027

Year: 2019

Mechanisms of activation induced by antiphospholipid antibodies in multiple sclerosis: Potential biomarkers of disease?

DOI: 10.1016/j.jim.2019.112663

Year: 2019

Evaluation of Epstein‐Barr virus‐specific antibodies in Cypriot multiple sclerosis patients

DOI: 10.1016/j.molimm.2018.12.010

Year: 2019

The possible role of an autoimmune mechanism in the etiopathogenesis of Parkinson’s disease

DOI: 10.1016/j.jocn.2018.06.004

Year: 2018

The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis.

DOI: 10.1016/j.molimm.2016.05.022

Year: 2016

The association between IgM and IgG antibodies against cardiolipin, beta 2-glycoprotein I and Domain I of beta 2-glycoprotein I with disease profile in patients with multiple sclerosis

DOI:

Year: 2015

Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome.

DOI: 10.1182/blood-2014-05-577569

Year: 2014

How Can Harmful Mutations Be Managed or Treated?

What is the Role of Genetics in Cancer Treatment?

What Makes a Mutation Harmful?

What types of genetic mutations are associated with PAH exposure?

How is HbS Diagnosed?

Which Genes are Involved in Autism Spectrum Disorder?

What are the Implications for Family Planning?

What is the Neutral Theory?

What Protective Measures Can Be Taken?

How Does Biotechnology Impact Environmental Conservation?

Partnered Content Networks

Relevant Topics